Neonatal diabetes: How research unravelling the genetic puzzle has both widened our understanding of pancreatic development whilst improving children's quality of life

Hormone Research

Volumn 67, Issue 2, 2007, Pages 77-83

  Shield, Julian P H ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

Neonatal diabetes; Permanent; Transient

Indexed keywords

GENE PRODUCT; GLUCOKINASE; INSULIN; INSULIN PROMOTER FACTOR 1; PROTEIN KCNJ11; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

AUTOSOMAL RECESSIVE DISORDER; CEREBELLUM HYPOPLASIA; CHROMOSOME 6Q; CHROMOSOME ABERRATION; COMORBIDITY; CONTINUOUS INFUSION; DIABETES MELLITUS; GENETIC ANALYSIS; GLYCEMIC CONTROL; HUMAN; MEDICAL RESEARCH; NEWBORN; NEWBORN DISEASE; ORGANOGENESIS; PANCREAS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; QUALITY OF LIFE; RARE DISEASE; SHORT SURVEY; WOLCOTT RALLISON SYNDROME;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 6; DIABETES MELLITUS, TYPE 1; EIF-2 KINASE; FORKHEAD TRANSCRIPTION FACTORS; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HOMEODOMAIN PROTEINS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INSULIN; INSULIN INFUSION SYSTEMS; PANCREAS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 33847356943     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096354     Document Type: Short Survey

References (48)

1. Kitselle: Jb Kinderheilk 1852; 18.
2. Iafusco D, Stazi MA, Cotichini R, et al: Permanent diabetes mellitus in the first year of life. Diabetologia 2002;45:798-804.
3. Shield JP, Gardner RJ, Wadsworth EJ, et al: Aetiopathology and genetic basis of neonatal diabetes. Arch Dis Child Fetal Neonatal Ed 1997;76:F39-F42.
4. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF: Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997;15:106-110.
5. Stoffers DA, Stanojevic V, Habener JF: Insulin promoter factor-1 gene mutation linked to early-onset type 2 diabetes mellitus directs expression of a dominant negative isoprotein. J Clin Invest 1998;102:232-241.
6. Hani EH, Stoffers DA, Chevre JC, et al: Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 1999;104:R41-R48.
7. Schwitzgebel VM, Mamin A, Brun T, et al: Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab 2003;88:4398-4406.
8. Temple IK, Gardner RJ, Mackay DJ, Barber JC, Robinson DO, Shield JP: Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes 2000;49:1359-1366.
9. Slingerland AS, Hattersley AT: Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment. Ann Med 2005;37:186-195.
10. Temple IK, James RS, Crolla JA, et al: An imprinted gene(s) for diabetes? Nat Genet 1995;9:110-112.
11. Temple IK, Gardner RJ, Robinson DO, et al: Further evidence for an imprinted gene for neonatal diabetes localised to chromosome 6q22-q23. Hum Mol Genet 1996;5:1117-1121.
12. Cave H, Polak M, Drunat S, Denamur E, Czernichow P: Refinement of the 6q chromosomal region implicated in transient neonatal diabetes. Diabetes 2000;49:108-113.
13. Gardner RJ, Mackay DJ, Mungall AJ, et al: An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet 2000;9:589-596.
14. Ma D, Shield JP, Dean W, et al: Impaired glucose homeostasis in transgenic mice expressing the human transient neonatal diabetes mellitus locus, TNDM. J Clin Invest 2004;114:339-348.
15. Polychronakos C, Xiaoyu D: Graded Overexpression of ZAC Impairs Glucose Stimulated Insulin Secretion in Beta-Cells. Washington, American Diabetes Association, 2006, 190-OR.
16. Valerio G, Franzese A, Salerno M, et al: Betacell dysfunction in classic transient neonatal diabetes is characterized by impaired insulin response to glucose but normal response to glucagon. Diabetes Care 2004;27:2405-2408.
17. Senee V, Vattem KM, Delepine M, et al: Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. Diabetes 2004;53:1876-1883.
18. Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C: EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000;25:406-409.
19. Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D: Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell 2000;5:897-904.
20. Harding HP, Zeng H, Zhang Y, et al: Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell 2001;7:1153-1163.
21. Brunkow ME, Jeffery EW, Hjerrild KA, et al: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68-73.
22. Wildin RS, Ramsdell F, Peake J, et al: X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20.
23. Wildin RS, Smyk-Pearson S, Filipovich AH: Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002;39:537-545.
24. Ruemmele FM, Brousse N, Goulet O: Autoimmune enteropathy: molecular concepts. Curr Opin Gastroenterol 2004;20:587-591.
25. Baud O, Goulet O, Canioni D, et al: Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001;344:1758-1762.
26. Mazzolari E, Forino C, Fontana M, et al: A new case of IPEX receiving bone marrow transplantation. Bone Marrow Transplant 2005;35:1033-1034.
27. Njolstad PR, Sovik O, Cuesta-Munoz A, et al: Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001;344:1588-1592.
28. Njolstad PR, Sagen JV, Bjorkhaug L, et al: Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes 2003;52:2854-2860.
29. Porter JR, Shaw NJ, Barrett TG, Hattersley AT, Ellard S, Gloyn AL: Permanent neonatal diabetes in an Asian infant. J Pediatr 2005;146:131-133.
30. Gloyn AL, Ellard S, Shield JP, et al: Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes. Diabetologia 2002;45:290.
31. Gloyn AL, Pearson ER, Antcliff JF, et al: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-1849.
32. Gloyn AL, Reimann F, Girard C, et al: Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 2005;14:925-934.
33. Hattersley AT, Ashcroft FM: Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54:2503-2513.
34. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM: Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci USA 2004;101:17539-17544.
35. Sagen JV, Raeder H, Hathout E, et al: Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2:patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004;53:2713-2718.
36. Klupa T, Edghill EL, Nazim J, et al: The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia 2005;48:1029-1031.
37. Pearson EFI, Njolstad P, Malecki M, Flanagan S, Larkin B, Ashcroft F, Klimes I, Codner E, Iotova V, Slingerland A, Shield J, Robert J-J, Holst J, Clark P, Ellard S, Sovik O, Polak M, Hattersley A: Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. New Engl J Med 2006;355:467-477.
38. Hoveyda N, Shield JP, Garrett C, et al: Neonatal diabetes mellitus and cerebellar hypoplasia/agenesis: report of a new recessive syndrome. J Med Genet 1999;36:700-704.
39. Sellick GS, Barker KT, Stolte-Dijkstra I, et al: Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet 2004;36:1301-1305.
40. Yorifuji T, Kurokawa K, Mamada M, et al: Neonatal diabetes mellitus and neonatal polycystic, dysplastic kidneys: phenotypically discordant recurrence of a mutation in the hepatocyte nuclear factor-1beta gene due to germline mosaicism. J Clin Endocrinol Metab 2004;89:2905-2908.
41. Mitchell J, Punthakee Z, Lo B, et al: Neonatal diabetes, with hypoplastic pancreas, intestinal atresia and gall bladder hypoplasia: search for the aetiology of a new autosomal recessive syndrome. Diabetologia 2004;47:2160-2167.
42. Verwest AM, Poelman M, Dinjens WN, et al: Absence of a PDX-1 mutation and normal gastroduodenal immunohistology in a child with pancreatic agenesis. Virchows Arch 2000;437:680-684.
43. Ashraf A, Abdullatif H, Hardin W, Moates JM: Unusual case of neonatal diabetes mellitus due to congenital pancreas agenesis. Pediatr Diabetes 2005;6:239-243.
44. Senee V, Chelala C, Duchatelet S, et al: Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet 2006;38:682-687.
45. Jeha GS, Venkatesh MP, Edelen RC, Kienstra KA, Karaviti L, Fernandes CJ: Neonatal diabetes mellitus: patient reports and review of current knowledge and clinical practice. J Pediatr Endocrinol Metab 2005;18:1095-1102.
46. Polak M, Shield J: Neonatal and very-early-onset diabetes mellitus. Semin Neonatol 2004;9:59-65.
47. Fosel S: Transient and permanent neonatal diabetes. Eur J Pediatr 1995;154:944-948.
48. Sperling MA: Neonatal diabetes mellitus: from understudy to center stage. Curr Opin Pediatr 2005;17:512-518.